SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1
Inhibitor) in Combination With Apatinib in Patients With Hepatocellular Carcinoma(HCC).This
study aims to evaluate the safety and efficacy of SHR-1210 combination with Apatinib as a
preoperative treatment of HCC.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University